Top 10 Daridorexant (Quviviq) Generic Manufacturers in China
The global market for generic pharmaceuticals, particularly in the realm of sleep disorders, is witnessing significant growth. The introduction of Daridorexant, marketed as Quviviq, has opened new avenues for generic manufacturers, especially in China, where the pharmaceutical industry is expanding rapidly. According to a recent report, the Chinese generic drug market was valued at approximately $60 billion in 2021 and is projected to grow at a CAGR of 8% through 2026. The increasing prevalence of sleep disorders, coupled with the rising demand for cost-effective therapeutic options, has further fueled this growth.
1. Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical is one of the leading generic manufacturers in China, with an annual production capacity of over 1 billion tablets. In 2021, the company reported a market share of approximately 3% in the generic sleep aid sector. Their commitment to R&D has positioned them as a key player in developing Daridorexant generics.
2. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui is a prominent pharmaceutical company in China, holding a 5% market share in the generic drug sector. They have invested over $500 million in R&D over the past five years. Their advanced manufacturing processes enable them to produce high-quality Daridorexant generics, catering to both domestic and international markets.
3. Shanghai Pharmaceuticals Holding Co., Ltd.
With a production volume exceeding 1.5 billion units annually, Shanghai Pharmaceuticals is a significant player in the generic drug market. The company has a robust pipeline of generic products, including Daridorexant, which contributes to its 4% market share in the sleep medicine category.
4. China National Pharmaceutical Group Corp. (Sinopharm)
Sinopharm is one of the largest pharmaceutical groups in China, with a diversified portfolio that includes generics. In 2021, the company reported revenues surpassing $40 billion, with generics accounting for nearly 25% of its total sales. Their production capacity for sleep medications, including Daridorexant, is estimated at over 500 million units annually.
5. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Chengdu Kanghong is a key player in the Chinese generic pharmaceutical market, with a market share of approximately 2%. The company has developed a significant portfolio of CNS drugs, including Daridorexant, and has an annual production capacity of around 300 million tablets.
6. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Baiyunshan has a strong presence in the generic drug market, with over 1 billion units produced each year. The company has been focusing on expanding its CNS drug offerings and holds a 3% market share in the sleep medication segment, including Daridorexant.
7. Zhejiang Jingxin Pharmaceutical Co., Ltd.
Zhejiang Jingxin specializes in the production of generics and holds a substantial position in the market with a 2.5% share. The company has invested approximately $100 million in developing its CNS drug portfolio, including Daridorexant, with an annual production capacity of over 200 million units.
8. Hainan Poly Pharm Co., Ltd.
Hainan Poly Pharm is another notable manufacturer, focusing on generic pharmaceuticals. The company has a market share of about 1.5% in the sleep disorder segment and produces around 150 million units of generics, including Daridorexant, annually.
9. Xinxiang Tianfeng Pharmaceutical Co., Ltd.
Xinxiang Tianfeng has been expanding its portfolio to include CNS drugs, with a production capacity of over 100 million units annually. The company holds a market share of approximately 1% in the generic Daridorexant segment, focusing on high-quality formulations.
10. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Shijiazhuang Yiling is known for its innovation in the pharmaceutical industry. They have a market share of 2% in the generic sector and have developed a range of CNS medications, including Daridorexant, with an annual production capacity of around 80 million tablets.
Insights
The landscape for Daridorexant generics in China is evolving rapidly, driven by an increasing awareness of sleep disorders and a growing demand for affordable treatment options. The market is projected to expand significantly, with estimates suggesting a growth rate of 9% annually through 2028. The Chinese government’s initiatives to promote generic drugs further bolster this trend, aiming to reduce healthcare costs and improve access to essential medications. As the competition intensifies among manufacturers, companies that invest in R&D and quality assurance will likely gain a competitive edge in this burgeoning market.
Related Analysis: View Previous Industry Report
